Abiopharma

Acumen Pharmaceuticals Inc (ABOS) Announces Clinical Trial Update Acumen Pharmaceuticals Inc (ABOS) provided an update on its clinical development programs. Clinical Development Highlights:

• Drug Program: appear, person
• Diseases/Conditions: Alzheimer’s disease (AD), bioanalytical assays Charlottesville
• Collaboration: Acumen Pharmaceuticals, Inc.
  • targeting antibodies may support therapeutic development. Other expected uses for ADDLs are as a quantitative standard in assays aimed at measuring soluble AßOs or AßO auto-antibodies in patient biofluids. “These research efforts towards developing a reliable model of AßOs will contribute to the greater body of knowledge around oligomers and Alzheimer’s disease,” said Eric Siemers, M.D., Chief Medical Officer at Acumen Pharmaceuticals. “AßOs have been a lesser studied target in Alzheimer’s disease. We expect our ongoing Phase 1 clinical trial of ACU193 to provide proof of mechanism data that we believe will shed additional light on the role of oligomers in Alzheimer’s disease.” The poster, “Preparation and qualification of soluble amyloid beta oligomers for use in bioanalytic assays supporting Alzheimer’s disease therapeutics” (P4-178), will be presented on Wednesday, Aug. 3, 2022